Cord Blood Banking Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service (Sample Preservation & Storage, Sample Analysis, Sample Processing, Sample Collection & Transportation), By Component (Cord Blood v/s Cord Tissue), By Application (Cancer Disease, Diabetes, Blood Disease, Immune Disorders, Metabolic Disorders, Others), By Sector (Public Cord Blood Banks v/s Private cord Blood Banks), By Company, and By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 20.11 Billion
CAGR (2026-2031)	11.78%
Fastest Growing Segment	Private cord Blood Banks
Largest Market	North America
Market Size (2031)	USD 39.23 Billion

Market Overview

The Global Cord Blood Banking Market will grow from USD 20.11 Billion in 2025 to USD 39.23 Billion by 2031 at a 11.78% CAGR. Cord blood banking involves the collection and cryopreservation of hematopoietic stem cells from the umbilical cord and placenta immediately following childbirth for potential therapeutic applications. The market is primarily driven by the rising prevalence of chronic hematological disorders and the proven clinical efficacy of stem cell transplantation in treating genetic and immune conditions. Furthermore, expanding research into regenerative medicine continues to validate the medical utility of these biological resources, thereby reinforcing the imperative for preservation among expectant parents and healthcare providers.

Despite these strong growth factors, the sector faces a significant challenge regarding the high cost of initial collection and recurring storage fees, which restricts accessibility for a broad demographic. This financial barrier is compounded by a lack of uniform insurance reimbursement policies for private banking. According to the World Marrow Donor Association, in 2026, the global registry listed 755,069 cord blood units available for patient matching. While this figure indicates a substantial inventory within the public domain, the prohibitive expense associated with family banking remains a primary restraint on wider market expansion.

Key Market Drivers

Rising Prevalence of Chronic and Genetic Disorders Treatable with Stem Cells is the primary force propelling market expansion. As the incidence of conditions such as leukemia, lymphoma, and sickle cell anemia increases, the clinical necessity for hematopoietic stem cell transplantation becomes more critical, directly incentivizing the storage of cord blood. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025', there were an estimated 66,890 new cases of leukemia diagnosed in the United States alone, underscoring the urgent need for readily available stem cell resources. This escalating disease burden compels families to bank cord blood as a biological insurance policy, driving volume in the private sector. Consequently, leading industry players have scaled their operations to meet this demand; according to the FamiCord Group, April 2025, in the 'Annual Report 2024', the company had cumulatively stored over one million units of biological material, reflecting the robust growth and scale of private banking services.

Advancements in Regenerative Medicine and Clinical Research are further broadening the market’s scope beyond traditional hematological applications. Research into the therapeutic potential of cord blood for neurological conditions is yielding promising results, which validates the utility of banking services for future medical interventions. According to Cryo-Cell International, April 2025, in the article 'Cord Blood Offers Hope for Cerebral Palsy', a study published in Pediatrics demonstrated that children with cerebral palsy treated with cord blood showed significant improvements in gross motor skills compared to those undergoing rehabilitation alone. Such clinical validation transforms the perceived value of cord blood from a niche treatment for blood cancers into a versatile asset for regenerative therapies, thereby encouraging wider adoption among expectant parents and healthcare providers.

Download Free Sample Report

Key Market Challenges

The prohibitive cost associated with private banking services stands as a primary challenge hindering the growth of the Global Cord Blood Banking Market. Families are required to pay substantial initial collection and processing fees, followed by recurring annual storage charges, creating a significant financial barrier that excludes a large segment of the potential customer base. This expense is particularly burdensome given the lack of uniform insurance coverage, forcing parents to bear the full financial weight out-of-pocket. Consequently, this pricing structure limits the market's reach to high-net-worth individuals, effectively stunting mass adoption and scalability.

This economic restraint is further intensified by the disparity between the high cost of preservation and the limited clinical application of these resources. Prospective customers often struggle to justify the substantial investment when the likelihood of therapeutic use remains minimal compared to other stem cell sources. According to the Center for International Blood and Marrow Transplant Research, in 2025, umbilical cord blood represented only 3% of allogeneic transplants. This low utilization rate undermines the perceived return on investment for expectant parents, thereby serving as a direct and powerful check on the market’s overall growth trajectory.

Key Market Trends

Diversification into Cord Tissue and Placental Banking Services is rapidly gaining traction as companies broaden their portfolios beyond traditional hematopoietic stem cell storage. By preserving mesenchymal stem cells found in the umbilical cord tissue and placenta, banks are unlocking new revenue streams and addressing the growing demand for regenerative therapies targeting muscle and nerve repair. This strategy effectively increases the lifetime value derived from each client while mitigating the pressure of stagnant blood collection rates. The financial impact of this service expansion is evident in the recent performance of leading operators; according to the FamiCord Group, August 2025, in the 'Interim Statement H1 2025', the company reported a 14.6% increase in first-half revenue to €43.6 million, a growth trajectory driven significantly by the successful commercial rollout of its placental tissue banking services across Europe.

Strategic Industry Consolidation through Mergers and Acquisitions is simultaneously reshaping the sector as major players absorb smaller entities to optimize operational efficiency. The high fixed costs associated with long-term cryopreservation and regulatory compliance favor well-capitalized conglomerates that can integrate banking into broader reproductive health ecosystems, thereby enabling cross-selling opportunities. This trend toward significant corporate scale is exemplified by the financial results of market leaders that have aggregated such assets. According to CooperCompanies, December 2025, in the 'Fourth Quarter and Full Year 2025 Results', the CooperSurgical division, which encompasses its newborn stem cell preservation operations, reported fiscal year revenue of $1.35 billion, reflecting the robust capacity and market footprint achieved through these integrated healthcare platforms.

Segmental Insights

The Private Cord Blood Banks segment currently stands as the fastest growing category within the Global Cord Blood Banking Market. This rapid expansion is primarily driven by the increasing inclination of parents toward securing biological insurance for their families, ensuring exclusive access to stem cells for potential future autologous use. Furthermore, advancements in regenerative medicine have broadened the scope of treatable conditions, incentivizing families to invest in private storage despite higher costs compared to public donation. This trend is reinforced by targeted awareness campaigns and evolving service models that appeal to higher income demographics globally.

Regional Insights

North America maintains a dominant position in the global cord blood banking market due to widespread consumer awareness and established healthcare infrastructure. The region benefits from a supportive regulatory framework, specifically the guidelines established by the US Food and Drug Administration, which ensure high safety standards for stem cell storage. Additionally, the increasing prevalence of hematological disorders drives the demand for stem cell preservation services. A strong network of accredited public and private banks further supports market expansion, making cord blood banking highly accessible to parents across the United States and Canada.

Recent Developments

• In May 2025, FamiCord AG, through its subsidiary Polski Bank Komórek Macierzystych (PBKM), executed a significant expansion of its operations in Central Europe. The company acquired an additional 69% stake in two established stem cell banks, Národní Centrum Pupečníkové Krve in the Czech Republic and Rodinná banka in Slovakia, increasing its total ownership in these entities to 95%. This acquisition, valued in the mid-single-digit million euros, consolidated the company's market position and facilitated the integration of processing and storage capabilities across its European network, further strengthening its footprint in the cord blood banking sector.
• In November 2024, StemCyte Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Biologics License Application regarding its allogeneic cord blood product, REGENECYTE. This regulatory milestone established the company as the first commercial entity to secure a biologics license for a cord blood stem cell therapy intended for unrelated donor transplantation. The product was approved for use in patients with specific disorders affecting the hematopoietic system, such as leukemia and immune deficiencies, marking a major advancement in the commercialization and standardization of cord blood therapies.
• In February 2024, CooperSurgical, the parent company of Cord Blood Registry (CBR), announced a strategic partnership with Fulgent Genetics to introduce exclusive newborn genetic screening options for families. Through this collaboration, CBR launched three new testing panels designed to utilize Fulgent's clinical diagnostic platform, enabling the screening of hundreds of genes associated with metabolic disorders, hearing loss, and other genetic conditions. This development expanded the service portfolio of the company within the Global Cord Blood Banking Market, offering clients additional health insights alongside standard stem cell preservation services.
• In February 2024, Americord Registry reported a significant clinical application of its stored stem cells involving the treatment of a client’s family member. The company facilitated the release and transfer of cord blood stem cells to India for the treatment of a grandmother diagnosed with motor neuron disease. This event highlighted the potential for intergenerational use of cryopreserved cord blood within families. The successful coordination with healthcare professionals for this international transfer demonstrated the logistical capabilities and therapeutic relevance of private banking in addressing progressive neurological disorders.

Key Market Players

• Americord Registry LLC
• Covis Group
• Cordlife Group Limited
• Cryo-Cell International, Inc.
• FamiCord Group
• Perkinelmer Inc.
• Lifecell International Pvt. Ltd.
• ViaCord LLC
• Global Cord Blood Corporation
• StemCyte, Inc.

By Service	By Component	By Application	By Sector	By Region
Sample Preservation & Storage Sample Analysis Sample Processing Sample Collection & Transportation	Cord Blood v/s Cord Tissue	Cancer Disease Diabetes Blood Disease Immune Disorders Metabolic Disorders Others	Public Cord Blood Banks v/s Private cord Blood Banks	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cord Blood Banking Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cord Blood Banking Market, By Service:

• Sample Preservation & Storage
• Sample Analysis
• Sample Processing
• Sample Collection & Transportation

• Cord Blood Banking Market, By Component:

• Cord Blood v/s Cord Tissue

• Cord Blood Banking Market, By Application:

• Cancer Disease
• Diabetes
• Blood Disease
• Immune Disorders
• Metabolic Disorders
• Others

• Cord Blood Banking Market, By Sector:

• Public Cord Blood Banks v/s Private cord Blood Banks

• Cord Blood Banking Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE